| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 98 | 2024 | 1766 | 13.380 |
Why?
|
| Cystectomy | 16 | 2023 | 105 | 4.970 |
Why?
|
| Patient Readmission | 18 | 2023 | 351 | 4.440 |
Why?
|
| Urinary Bladder Neoplasms | 20 | 2023 | 394 | 4.260 |
Why?
|
| Urology | 15 | 2024 | 117 | 3.590 |
Why?
|
| Delivery of Health Care | 21 | 2023 | 433 | 3.550 |
Why?
|
| Prostate-Specific Antigen | 20 | 2024 | 358 | 3.400 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 7 | 2024 | 121 | 3.320 |
Why?
|
| Prostatectomy | 21 | 2023 | 476 | 3.270 |
Why?
|
| Androgen Antagonists | 12 | 2024 | 154 | 3.220 |
Why?
|
| Male | 148 | 2024 | 42099 | 2.390 |
Why?
|
| Aged | 95 | 2024 | 18994 | 2.000 |
Why?
|
| Humans | 183 | 2024 | 88786 | 1.980 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 1146 | 1.870 |
Why?
|
| United States | 66 | 2024 | 6926 | 1.820 |
Why?
|
| Androstenes | 6 | 2024 | 45 | 1.820 |
Why?
|
| Quality of Health Care | 13 | 2019 | 384 | 1.780 |
Why?
|
| Phenylthiohydantoin | 5 | 2024 | 48 | 1.760 |
Why?
|
| Survivors | 9 | 2016 | 233 | 1.680 |
Why?
|
| Urologic Neoplasms | 5 | 2024 | 81 | 1.640 |
Why?
|
| Medical Oncology | 4 | 2024 | 379 | 1.630 |
Why?
|
| Postoperative Complications | 14 | 2020 | 2273 | 1.620 |
Why?
|
| Quality of Life | 20 | 2024 | 1658 | 1.570 |
Why?
|
| Prostatic Hyperplasia | 3 | 2019 | 91 | 1.560 |
Why?
|
| Cancer Survivors | 5 | 2022 | 95 | 1.550 |
Why?
|
| Veterans | 4 | 2021 | 83 | 1.540 |
Why?
|
| Medicare | 27 | 2023 | 422 | 1.520 |
Why?
|
| Veterans Health | 7 | 2020 | 16 | 1.520 |
Why?
|
| Prostate | 9 | 2023 | 393 | 1.520 |
Why?
|
| Survivorship | 5 | 2021 | 20 | 1.500 |
Why?
|
| Telemedicine | 7 | 2024 | 185 | 1.480 |
Why?
|
| Practice Patterns, Physicians' | 17 | 2024 | 598 | 1.440 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2021 | 31 | 1.390 |
Why?
|
| Self-Management | 3 | 2019 | 39 | 1.360 |
Why?
|
| Patient Discharge | 8 | 2023 | 320 | 1.320 |
Why?
|
| Primary Health Care | 5 | 2020 | 350 | 1.280 |
Why?
|
| Research Design | 7 | 2021 | 597 | 1.240 |
Why?
|
| Ketoconazole | 2 | 2024 | 26 | 1.170 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 6754 | 1.150 |
Why?
|
| Urinary Catheterization | 3 | 2024 | 36 | 1.080 |
Why?
|
| Sexual Partners | 7 | 2022 | 99 | 1.030 |
Why?
|
| Physicians, Primary Care | 3 | 2024 | 105 | 1.020 |
Why?
|
| Neoplasms | 7 | 2023 | 3020 | 0.990 |
Why?
|
| Osteoporosis | 2 | 2017 | 122 | 0.990 |
Why?
|
| Retrospective Studies | 43 | 2024 | 8951 | 0.980 |
Why?
|
| Surgical Procedures, Operative | 5 | 2024 | 205 | 0.970 |
Why?
|
| Urologists | 7 | 2024 | 29 | 0.970 |
Why?
|
| Robotics | 4 | 2012 | 269 | 0.960 |
Why?
|
| Treatment Outcome | 25 | 2024 | 8170 | 0.960 |
Why?
|
| Middle Aged | 48 | 2024 | 25759 | 0.930 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 156 | 0.920 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 207 | 0.920 |
Why?
|
| Medicare Part D | 3 | 2021 | 10 | 0.840 |
Why?
|
| Bibliometrics | 2 | 2019 | 37 | 0.830 |
Why?
|
| Watchful Waiting | 6 | 2024 | 63 | 0.830 |
Why?
|
| Patient Care | 1 | 2023 | 102 | 0.820 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2019 | 114 | 0.810 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 357 | 0.800 |
Why?
|
| Aftercare | 4 | 2023 | 87 | 0.780 |
Why?
|
| Names | 1 | 2021 | 10 | 0.770 |
Why?
|
| Life Expectancy | 6 | 2021 | 88 | 0.770 |
Why?
|
| Surgeons | 3 | 2024 | 247 | 0.760 |
Why?
|
| Nitriles | 7 | 2024 | 160 | 0.730 |
Why?
|
| Drug Prescriptions | 3 | 2021 | 144 | 0.730 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 1988 | 0.720 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 328 | 0.720 |
Why?
|
| Reimbursement, Incentive | 1 | 2020 | 37 | 0.710 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2017 | 176 | 0.700 |
Why?
|
| Physicians | 3 | 2023 | 689 | 0.700 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2019 | 10 | 0.700 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2022 | 69 | 0.700 |
Why?
|
| Urinary Diversion | 2 | 2017 | 42 | 0.690 |
Why?
|
| Information Dissemination | 2 | 2017 | 113 | 0.680 |
Why?
|
| Health Expenditures | 3 | 2020 | 91 | 0.670 |
Why?
|
| Electronic Health Records | 3 | 2021 | 340 | 0.670 |
Why?
|
| Orchiectomy | 2 | 2018 | 72 | 0.660 |
Why?
|
| SEER Program | 16 | 2022 | 197 | 0.660 |
Why?
|
| Castration | 1 | 2018 | 41 | 0.660 |
Why?
|
| Accountable Care Organizations | 5 | 2019 | 13 | 0.650 |
Why?
|
| Logistic Models | 10 | 2021 | 1210 | 0.650 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2019 | 101 | 0.650 |
Why?
|
| Publishing | 1 | 2019 | 90 | 0.640 |
Why?
|
| Models, Theoretical | 2 | 2019 | 491 | 0.640 |
Why?
|
| Erectile Dysfunction | 7 | 2023 | 75 | 0.630 |
Why?
|
| Spouses | 2 | 2017 | 32 | 0.620 |
Why?
|
| Length of Stay | 6 | 2020 | 731 | 0.610 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 47 | 0.600 |
Why?
|
| Urinary Bladder | 2 | 2017 | 246 | 0.600 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 56 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1039 | 0.600 |
Why?
|
| Time Factors | 14 | 2024 | 5309 | 0.590 |
Why?
|
| Machine Learning | 1 | 2020 | 250 | 0.590 |
Why?
|
| Insurance Coverage | 2 | 2020 | 118 | 0.590 |
Why?
|
| Female | 43 | 2024 | 45856 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2019 | 58 | 0.570 |
Why?
|
| Odds Ratio | 8 | 2019 | 685 | 0.560 |
Why?
|
| Interviews as Topic | 3 | 2019 | 333 | 0.560 |
Why?
|
| Health Education | 1 | 2017 | 105 | 0.560 |
Why?
|
| Kidney Neoplasms | 4 | 2010 | 634 | 0.550 |
Why?
|
| Survival Rate | 11 | 2020 | 1880 | 0.550 |
Why?
|
| Fractures, Bone | 1 | 2017 | 126 | 0.550 |
Why?
|
| Replantation | 1 | 2016 | 36 | 0.550 |
Why?
|
| Hospital Costs | 1 | 2017 | 107 | 0.540 |
Why?
|
| Prognosis | 12 | 2024 | 3753 | 0.540 |
Why?
|
| Ureteral Obstruction | 1 | 2016 | 67 | 0.530 |
Why?
|
| Self Care | 1 | 2017 | 164 | 0.530 |
Why?
|
| Consumer Health Information | 1 | 2015 | 14 | 0.520 |
Why?
|
| Ureter | 1 | 2016 | 93 | 0.510 |
Why?
|
| Unnecessary Procedures | 6 | 2020 | 51 | 0.490 |
Why?
|
| Rural Population | 3 | 2015 | 142 | 0.480 |
Why?
|
| Benzamides | 5 | 2024 | 237 | 0.480 |
Why?
|
| Cohort Studies | 15 | 2021 | 2850 | 0.480 |
Why?
|
| Health Care Costs | 7 | 2019 | 235 | 0.480 |
Why?
|
| Cost of Illness | 2 | 2017 | 147 | 0.470 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 46 | 0.470 |
Why?
|
| Exercise Therapy | 1 | 2014 | 81 | 0.470 |
Why?
|
| Biomedical Research | 2 | 2018 | 397 | 0.460 |
Why?
|
| Androgens | 3 | 2023 | 175 | 0.450 |
Why?
|
| Qualitative Research | 3 | 2024 | 288 | 0.450 |
Why?
|
| Robotic Surgical Procedures | 3 | 2023 | 300 | 0.440 |
Why?
|
| Health Services Accessibility | 5 | 2020 | 424 | 0.430 |
Why?
|
| Peripheral Nerves | 1 | 2013 | 37 | 0.430 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 2607 | 0.430 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 190 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1354 | 0.420 |
Why?
|
| Physician-Patient Relations | 2 | 2015 | 625 | 0.420 |
Why?
|
| Quality Improvement | 5 | 2022 | 446 | 0.420 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 986 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 172 | 0.410 |
Why?
|
| Automation | 1 | 2012 | 111 | 0.410 |
Why?
|
| Communication | 1 | 2015 | 457 | 0.400 |
Why?
|
| Taxoids | 2 | 2023 | 130 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2024 | 858 | 0.390 |
Why?
|
| Cost Savings | 4 | 2019 | 69 | 0.390 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1530 | 0.390 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 53 | 0.390 |
Why?
|
| Urinary Incontinence | 4 | 2023 | 213 | 0.370 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 25 | 0.360 |
Why?
|
| Lymph Node Excision | 2 | 2010 | 220 | 0.360 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 570 | 0.360 |
Why?
|
| Guideline Adherence | 5 | 2021 | 228 | 0.360 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1193 | 0.350 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2410 | 0.340 |
Why?
|
| Recovery of Function | 4 | 2023 | 292 | 0.340 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 98 | 0.330 |
Why?
|
| BCG Vaccine | 1 | 2009 | 34 | 0.330 |
Why?
|
| Health Services Needs and Demand | 3 | 2020 | 103 | 0.330 |
Why?
|
| Urologic Surgical Procedures | 1 | 2010 | 147 | 0.320 |
Why?
|
| Drug Industry | 3 | 2023 | 54 | 0.320 |
Why?
|
| Adult | 17 | 2024 | 26414 | 0.320 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1212 | 0.320 |
Why?
|
| Retroperitoneal Space | 1 | 2008 | 38 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2645 | 0.310 |
Why?
|
| Health Resources | 2 | 2020 | 81 | 0.310 |
Why?
|
| Risk Factors | 8 | 2019 | 5446 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2546 | 0.310 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 277 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 831 | 0.300 |
Why?
|
| Health Care Reform | 3 | 2016 | 85 | 0.300 |
Why?
|
| Clinical Protocols | 2 | 2018 | 158 | 0.290 |
Why?
|
| Registries | 4 | 2023 | 765 | 0.290 |
Why?
|
| Prospective Studies | 8 | 2023 | 4255 | 0.290 |
Why?
|
| Sexual Behavior | 7 | 2022 | 308 | 0.290 |
Why?
|
| Health Services | 2 | 2017 | 56 | 0.290 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 113 | 0.290 |
Why?
|
| Hematuria | 2 | 2024 | 50 | 0.280 |
Why?
|
| Penile Erection | 2 | 2018 | 22 | 0.280 |
Why?
|
| Perioperative Care | 2 | 2019 | 168 | 0.280 |
Why?
|
| Reimbursement Mechanisms | 2 | 2019 | 41 | 0.280 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 372 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 363 | 0.270 |
Why?
|
| Patient Preference | 2 | 2018 | 108 | 0.270 |
Why?
|
| Age Factors | 3 | 2019 | 1861 | 0.270 |
Why?
|
| Kallikreins | 2 | 2016 | 49 | 0.270 |
Why?
|
| Diffusion of Innovation | 4 | 2014 | 71 | 0.260 |
Why?
|
| Cystoscopy | 2 | 2024 | 39 | 0.260 |
Why?
|
| Remote Consultation | 2 | 2015 | 16 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 304 | 0.250 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 411 | 0.250 |
Why?
|
| Urologic Diseases | 2 | 2015 | 44 | 0.250 |
Why?
|
| Biopsy | 4 | 2022 | 1180 | 0.240 |
Why?
|
| Urinary Retention | 1 | 2024 | 42 | 0.240 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.240 |
Why?
|
| Body Mass Index | 1 | 2007 | 765 | 0.230 |
Why?
|
| Incidence | 3 | 2021 | 1592 | 0.230 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 107 | 0.230 |
Why?
|
| Pyrimidinones | 1 | 2023 | 37 | 0.230 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1698 | 0.230 |
Why?
|
| Certificate of Need | 2 | 2012 | 3 | 0.220 |
Why?
|
| Risk Adjustment | 2 | 2019 | 38 | 0.210 |
Why?
|
| Sexual Health | 1 | 2022 | 17 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2023 | 531 | 0.200 |
Why?
|
| Mass Screening | 3 | 2019 | 631 | 0.200 |
Why?
|
| Psychometrics | 2 | 2021 | 329 | 0.200 |
Why?
|
| Health Services Misuse | 2 | 2012 | 19 | 0.200 |
Why?
|
| Patient Selection | 3 | 2020 | 682 | 0.200 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2023 | 126 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 575 | 0.200 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1711 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2020 | 849 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 481 | 0.190 |
Why?
|
| Laparoscopy | 1 | 2008 | 771 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 384 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 16 | 0.190 |
Why?
|
| Hospitalization | 2 | 2017 | 873 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2015 | 121 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 848 | 0.190 |
Why?
|
| Data Accuracy | 2 | 2018 | 31 | 0.190 |
Why?
|
| Obesity | 1 | 2007 | 960 | 0.190 |
Why?
|
| Oncology Service, Hospital | 1 | 2020 | 6 | 0.190 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.190 |
Why?
|
| Urination Disorders | 2 | 2011 | 50 | 0.190 |
Why?
|
| Pandemics | 3 | 2023 | 770 | 0.180 |
Why?
|
| Nephrectomy | 2 | 2016 | 293 | 0.180 |
Why?
|
| Patient Care Management | 2 | 2017 | 30 | 0.180 |
Why?
|
| Physical Fitness | 1 | 2020 | 51 | 0.180 |
Why?
|
| Urinary Catheters | 1 | 2019 | 6 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2019 | 18 | 0.170 |
Why?
|
| Florida | 1 | 2019 | 56 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 20 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 299 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 21 | 0.170 |
Why?
|
| Economics, Hospital | 1 | 2019 | 11 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2750 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 642 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2020 | 301 | 0.160 |
Why?
|
| Mastectomy | 1 | 2021 | 245 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 138 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2018 | 39 | 0.160 |
Why?
|
| Subacute Care | 1 | 2018 | 13 | 0.160 |
Why?
|
| Urethral Stricture | 1 | 2018 | 14 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 225 | 0.160 |
Why?
|
| Insurance Benefits | 1 | 2018 | 8 | 0.160 |
Why?
|
| Self-Help Devices | 1 | 2018 | 6 | 0.160 |
Why?
|
| Health Services Research | 2 | 2016 | 137 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1708 | 0.160 |
Why?
|
| Internet | 2 | 2017 | 318 | 0.150 |
Why?
|
| Physician Assistants | 2 | 2024 | 21 | 0.150 |
Why?
|
| Hand Disinfection | 1 | 2018 | 17 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 167 | 0.150 |
Why?
|
| Parents | 1 | 2021 | 286 | 0.150 |
Why?
|
| Men's Health | 1 | 2017 | 6 | 0.150 |
Why?
|
| Practice Management, Medical | 1 | 2017 | 23 | 0.150 |
Why?
|
| Teaching Materials | 1 | 2017 | 14 | 0.150 |
Why?
|
| Public Sector | 1 | 2017 | 12 | 0.150 |
Why?
|
| Urethra | 1 | 2018 | 115 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 235 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2017 | 32 | 0.150 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2017 | 35 | 0.150 |
Why?
|
| Exercise | 2 | 2023 | 322 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 46 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3648 | 0.140 |
Why?
|
| Nephrotomy | 1 | 2016 | 1 | 0.140 |
Why?
|
| Attitude to Health | 3 | 2014 | 222 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 94 | 0.140 |
Why?
|
| Hospital Communication Systems | 1 | 2016 | 4 | 0.140 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 129 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 565 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 2016 | 226 | 0.140 |
Why?
|
| Failure to Thrive | 1 | 2016 | 17 | 0.140 |
Why?
|
| Bone Density | 1 | 2017 | 209 | 0.140 |
Why?
|
| Information Seeking Behavior | 1 | 2016 | 14 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2016 | 83 | 0.140 |
Why?
|
| Japan | 1 | 2016 | 303 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1870 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2018 | 865 | 0.130 |
Why?
|
| General Surgery | 1 | 2018 | 235 | 0.130 |
Why?
|
| Language | 1 | 2017 | 154 | 0.130 |
Why?
|
| Creatinine | 1 | 2016 | 293 | 0.130 |
Why?
|
| Fever | 1 | 2016 | 127 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 434 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2020 | 777 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 275 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 273 | 0.130 |
Why?
|
| Denosumab | 1 | 2014 | 2 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1849 | 0.120 |
Why?
|
| Reproductive Health | 1 | 2015 | 34 | 0.120 |
Why?
|
| Coitus | 1 | 2014 | 20 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2014 | 36 | 0.120 |
Why?
|
| American Cancer Society | 1 | 2014 | 13 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2017 | 356 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2017 | 321 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 105 | 0.120 |
Why?
|
| Environment | 1 | 2015 | 224 | 0.110 |
Why?
|
| Stents | 1 | 2016 | 393 | 0.110 |
Why?
|
| Technology Transfer | 1 | 2013 | 3 | 0.110 |
Why?
|
| Administration, Intravesical | 2 | 2011 | 32 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 440 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2014 | 216 | 0.110 |
Why?
|
| Adaptation, Psychological | 3 | 2022 | 165 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 308 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1107 | 0.110 |
Why?
|
| Health Promotion | 1 | 2014 | 161 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 146 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 268 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2021 | 1534 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 413 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2015 | 280 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 441 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 84 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 181 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 430 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2011 | 31 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 1041 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2016 | 2285 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 32 | 0.090 |
Why?
|
| Comorbidity | 3 | 2019 | 948 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 461 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 115 | 0.090 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 30 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 1170 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 368 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 965 | 0.080 |
Why?
|
| Valsalva Maneuver | 1 | 2008 | 6 | 0.080 |
Why?
|
| Dissection | 1 | 2008 | 44 | 0.080 |
Why?
|
| Insurance Claim Review | 2 | 2019 | 45 | 0.080 |
Why?
|
| Cough | 1 | 2008 | 55 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 6264 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 502 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 461 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 110 | 0.070 |
Why?
|
| Suburethral Slings | 1 | 2008 | 75 | 0.070 |
Why?
|
| Colectomy | 2 | 2019 | 172 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2019 | 120 | 0.070 |
Why?
|
| Adolescent | 2 | 2017 | 9197 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 780 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2986 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 126 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 287 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 404 | 0.070 |
Why?
|
| Decision Making | 2 | 2023 | 664 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 477 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 657 | 0.070 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2008 | 196 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 376 | 0.060 |
Why?
|
| Family Characteristics | 2 | 2014 | 49 | 0.060 |
Why?
|
| Videoconferencing | 1 | 2024 | 15 | 0.060 |
Why?
|
| Leuprolide | 1 | 2024 | 35 | 0.060 |
Why?
|
| Industry | 1 | 2023 | 17 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2023 | 59 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 583 | 0.050 |
Why?
|
| Medicaid | 2 | 2019 | 228 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2023 | 230 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 12 | 0.050 |
Why?
|
| England | 1 | 2022 | 38 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 319 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 63 | 0.050 |
Why?
|
| Group Practice | 1 | 2021 | 7 | 0.050 |
Why?
|
| Inpatients | 1 | 2024 | 310 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2344 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 163 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 255 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Data Collection | 1 | 2022 | 375 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2023 | 284 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 50 | 0.040 |
Why?
|
| Accreditation | 1 | 2020 | 61 | 0.040 |
Why?
|
| Income | 1 | 2020 | 82 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 299 | 0.040 |
Why?
|
| Drug Costs | 1 | 2020 | 63 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 80 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 178 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 210 | 0.040 |
Why?
|
| Marital Status | 1 | 2019 | 42 | 0.040 |
Why?
|
| Bias | 1 | 2019 | 131 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 175 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 71 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 681 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2018 | 14 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 518 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 281 | 0.040 |
Why?
|
| Michigan | 1 | 2018 | 53 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 266 | 0.040 |
Why?
|
| Holistic Health | 1 | 2017 | 9 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 233 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 160 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1835 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2017 | 39 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 328 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 617 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 575 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 304 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 390 | 0.030 |
Why?
|
| Medical Overuse | 1 | 2016 | 36 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 54 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1062 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 28 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2018 | 206 | 0.030 |
Why?
|
| Orgasm | 1 | 2014 | 9 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 782 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 207 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 172 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 224 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 295 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2012 | 42 | 0.030 |
Why?
|
| State Government | 1 | 2012 | 22 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 64 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 149 | 0.030 |
Why?
|
| Child | 1 | 2023 | 7112 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1482 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2010 | 67 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2011 | 186 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 209 | 0.020 |
Why?
|
| Urodynamics | 1 | 2008 | 122 | 0.020 |
Why?
|